Aprea Therapeutics Showcases Innovations at Upcoming Summit
Aprea Therapeutics, Inc. (NASDAQ: APRE) is making headlines as it prepares for two exciting presentations at the Maxim Healthcare Virtual Summit. This participation reflects Aprea's commitment to advancing precision oncology, a field that is rapidly evolving with the promise of targeted treatments.
Summit Presentation Highlights
Dr. Oren Gilad, the President and CEO of Aprea, will represent the company at the virtual summit, sharing insights and progress on their innovative approaches to cancer treatment.
Panel Discussion on Precision Oncology
One of the key sessions will focus on the "Precision and Immune Oncology Panel," scheduled for Wednesday from 2:00 to 3:00 PM ET. This session aims to delve into how precision medicine is reshaping cancer therapies, which is a core pillar of Aprea's strategic endeavors.
Engaging Fireside Chat
The second presentation by Dr. Gilad will be a fireside chat on Thursday from 3:30 to 4:00 PM ET. This informal discussion will allow for a deeper engagement on the innovative strategies Aprea is implementing, highlighting their dedication to developing cutting-edge solutions in oncology.
Understanding Aprea's Innovative Approach
Aprea Therapeutics focuses on precision oncology through synthetic lethality, a promising area that seeks to identify and exploit cancer cell vulnerabilities while sparing healthy tissues. The company's lead program, ATRN-119, is an investigative small-molecule ATR inhibitor. This therapy is designed for patients with specific solid tumors, and it exemplifies Aprea's commitment to personalized treatment.
Recent Developments
In addition to ATRN-119, Aprea has recently initiated clinical trials for APR-1051, an oral WEE1 inhibitor. These advancements underline Aprea's proactive stance in the oncology landscape and their objective to bring innovative therapies to patients in need.
Engaging with Aprea Therapeutics
Aprea Therapeutics encourages interested parties to engage further by visiting their investor relations website. This platform provides valuable information about their ongoing research, clinical trials, and overall mission to revolutionize cancer treatment.
Investor and Media Contacts
For additional inquiries, Mike Moyer from LifeSci Advisors can be reached for investor-related questions. Moreover, media inquiries can be directed to Ignacio Guerrero-Ros or David Schull at Russo Partners, who are available to shed more light on Aprea's initiatives and contributions to the field of oncology.
Frequently Asked Questions
What is Aprea Therapeutics known for?
Aprea Therapeutics is recognized for its focus on precision oncology through synthetic lethality, developing targeted therapies for cancer treatment.
Who will be presenting at the Maxim Healthcare Virtual Summit?
Dr. Oren Gilad, the President and CEO of Aprea Therapeutics, will be the primary presenter at the summit.
What are the key presentations at the summit?
The key presentations include a panel on "Precision and Immune Oncology" and a fireside chat discussing innovative oncology strategies.
What is ATRN-119?
ATRN-119 is Aprea's lead drug candidate, a small-molecule ATR inhibitor aimed at treating specific solid tumors.
How can I get in touch with Aprea Therapeutics?
For investor inquiries, Mike Moyer from LifeSci Advisors is available, and media inquiries should be directed to Russo Partners.